One major focus of our lab is the study and development of selective inhibitors of the ERK pathway to treat the tumors driven by ERK hyperactivation. Previously we found that activation of ERK output ...

In this study, we identify inhibition of osteoblast (OB) function as an additional pathogenic mechanism in CCL3-induced ... effects on OBs are mediated by ERK activation and subsequent ...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com/), a clinical-stage biotech company developing novel, first-in-class dual ...